trastuzumab
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
July, 2024
July 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Jun
trastuzumab
Jul 25, 2024, 20:48 |
Insight
Subcutaneous vs Intravenous Trastuzumab/Pertuzumab in HER2+ Breast Cancer
Dana-Farber’s Breast Oncology Center shared on X: "New in JCO Oncology Practice: Subcutaneous vs Intravenous…
Jun 29, 2024, 09:05 |
Blog
Erika Hamilton: Always worth major celebration when we see survival improve by 10 months in metastatic cancer
Erika Hamilton shared a post by Healthbook on LinkedIn, adding: "Always worth major celebration when we…
Jun 26, 2024, 06:07 |
Insight
Prognostic significance of Pan-Immune-Inflammation value in mBC treated with Trastuzumab Emtansine
Taha Koray Sahin, Medical Oncologist at Hacettepe University Hospitals, shared on X: “I am excited to…
Jun 6, 2024, 14:04 |
Insight
Elie G. Dib: TAPUR study has been presented at the 2024 ASCO Annual Meeting!
Elie G. Dib, Associate Director of the Haematology-Oncology Training Program at Saint Joseph Mercy Hospital,…
May 28, 2024, 14:34 |
Drugs
Paolo Tarantino: Impressive activity with tucatinib plus trastuzumab for HER2-mutated breast cancer
Paolo Tarantino shared on X: "Impressive activity with tucatinib plus trastuzumab for HER2-mutated breast cancer.…
May 17, 2024, 12:54 |
Insight
Piotr Wysocki: Anti-HER2 treatment in patients with advanced biliary cancer
Piotr Wysocki recently posted on LinkedIn: "The Targeted Agent and Profiling Utilization Registry (TAPUR) Study is…
May 16, 2024, 14:15 |
Insight
Elie G. Dib: Excited to share the results of the TAPUR study
Elie G. Dib, Associate Director of the Haematology-Oncology Training Program at Saint Joseph Mercy Hospital,…
May 15, 2024, 13:45 |
Blog
Sergio Cifuentes Canaval: Exciting insights from the MRI-guided optimization study in HER2+ breast cancer!
Sergio Cifuentes Canaval, Student Fellow at National Autonomous University of Mexico, shared a post on LinkedIn:…
May 11, 2024, 11:23 |
Insight
Matt Sagan: Moving from HER2+ to HER2-low to HER2- ultralow
Matt Sagan, Co-Founder and CEO of FiBioMed, shared a post by Paolo Tarantino on X,…
Apr 15, 2024, 14:38 |
Insight
New Paper Alert! Refining Treatment Approaches in Early Breast Cancer Patients with Pathologic Complete Response
Refining Treatment Approaches in Early Breast Cancer Patients with Pathologic Complete Response Authors: Carmine Valenza,…
Apr 8, 2024, 14:26 |
Drugs
Dana-Farber’s Breast Oncology Center is leading a trial for stage 1 HER2+ Breast Cancer of T-DM1 followed by SQ trastuzumab versus TH
Dana-Farber’s Breast Oncology Center posted on X: "We are leading a randomized Phase 2 trial for…
Mar 27, 2024, 13:02 |
Blog
Erman Akkus: ESMO-2023, hepatobiliary and pancreatic cancers
Erman Akkus, Medical Oncology Fellow at Ankara University, shared on X/Twitter: "ESMO-2023, hepatobiliary and pancreatic…
Mar 22, 2024, 16:49 |
Insight
Guilherme Nader Marta: CLEOPATRA trial analysis shows that complete response at first imaging re-evaluation correlates with longer PFS and OS
Guilherme Nader Marta, Oncology Fellow at Jules Bordet Institute, shared on LinkedIn: “Many patients with…
Mar 22, 2024, 06:12 |
Drugs
Paolo Tarantino: We’re running SATEEN, the first trial of sacituzumab govitecan + trastuzumab in patients with HER2 + MBC
Paolo Tarantino, Medical Oncologist and Research Fellow at Dana-Farber Cancer Institute, shared a post by Marta…
Feb 8, 2024, 17:54 |
Insight
Paolo Tarantino: Few treatments in oncology allow to achieve more than 50% intracranial response rates, with durable efficacy
Paolo Tarantino, Research Fellow at Dana-Farber Cancer Institute, shared ESMO Open's post on X/Twitter, adding: "One…
Dec 10, 2023, 17:32 |
Blog
Wafik S. El-Deiry: I wore my chemistry tie today in honor of your visit to Providence and Brown University
Wafik S. El-Deiry, the Director of the Legorreta Cancer Center of Brown University, posted on LinkedIn:…
Sep 21, 2023, 04:05 |
Drugs
Paolo Tarantino: The longest follow up to date of a metastatic trastuzumab trial.
Paolo Tarantino, a clinical research fellow at the Dana-Farber Cancer Institute, shared the following insight…
Jun 15, 2023, 15:56 |
Drugs
Patients with ERBB2 exon 20 insertion mutations showed particularly encouraging outcomes - Elie G. Dib
Excited to share that our study, published in JCO Precision Oncology, sheds light on the…
All:
18
Posts:
1 - 100
The largest philanthropic partnership in The V Foundation’s history - Dolphins Cancer Challenge
Glecirasib: A Promising Novel KRAS G12C Inhibitor in Clinical Development
How the Médecins Sans Frontières Journal Inspired a Lifetime of Humanitarian Service: Paul Spiegel
OncoDaily Party and Yvonne Award Photos - Part 1
Michael Douglas: The Untold Story of His Battle Against Cancer
Facebook
RSS Feed
Twitter
Linkedin
Youtube